Researchers Discover Cellular Recycling Centers Act as Hidden Reservoirs for Ovarian Cancer Drugs

LMS researchers discover that lysosomes act as drug reservoirs, affecting PARP inhibitor distribution and potentially causing cancer treatment resistance.

By: AXL Media

Published: Mar 18, 2026, 9:00 AM EDT

Source: Information for this report was sourced from Medical Research Council (MRC) Laboratory of Medical Sciences

Mapping the Invisible Disparities of Drug Distribution Within Tumors

New research published in Nature Communications has revealed that the effectiveness of cancer therapy is dictated by more than just a drug reaching a tumor. A team led by Dr. Louise Fets at the LMS used advanced mass spectrometry imaging to create high resolution maps of PARP inhibitors within human ovarian tumor samples. The study demonstrated that even when patients receive the same dosage, the actual concentration of the drug varies significantly across different regions of a single tumor. By keeping tumor slices alive in the laboratory, the investigators were able to observe how these targeted treatments spread through real human tissue, uncovering a complex landscape of high and low exposure zones that could be the primary driver of treatment failure and drug resistance.

The Discovery of Lysosomal Reservoirs in Ovarian Cancer Cells

The investigators identified that lysosomes, the small compartments typically responsible for recycling cellular waste, serve as unintended storage units for certain oncological treatments. These organelles pull in drug molecules and trap them, creating internal reservoirs that prevent the medication from spreading evenly throughout the cell. Dr. Carmen Ramirez Moncayo, the study's first author, noted that this build up at the single cell level was a surprising find, as it essentially turns the lysosomes into slow release stores. While this can increase the total exposure time for some cells, it simultaneously leaves neighboring cells relatively unexposed, providing a sanctuary where cancer can survive and eventually mutate.

Variability Among PARP Inhibitors and Implications for Treatment Choice

A critical finding of the research is that not all medications within the same class interact with lysosomes in the same manner. The study revealed that lysosomal storage specifically affects drugs such as rucaparib and niraparib, whereas olaparib does not exhibit the same tendency to accumulate in these compartments. This distinction is vital for clinicians, as it suggests that the chemical structure of a specific PARP inhibitor determines its journey through the cellular landscape. Understanding these differences allows researchers to better predict which drugs will remain active in the cytoplasm and which will be sequestered, providing a new metric for evalua...